INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the 5^th^ most common cancer and 3^rd^ leading cause of cancer-related death worldwide \[[@R1]\]. The majority of HCCs are diagnosed in a stage that is not eligible for curative resection, i.e., intermediate or advanced stage HCC. For intermediate stage HCC, transarterial chemoembolization (TACE) is the recommended treatment \[[@R2]\]. A survival benefit has been demonstrated for TACE-treated HCC over the best supportive care \[[@R3]\] alone.

Different embolic agents are available for use in the TACE procedure. TACE using Lipiodol is the most common technique for the treatment of HCC \[[@R4]\]. The use of drug eluting beads (DEB) offers another safe and efficient treatment option, even in advanced HCC \[[@R5]--[@R7]\]. Conventional Lipiodol-TACE has two major drawbacks: (1) it has ill-defined and prolonged vascular occlusion over a half-time from 5 to 12 weeks \[[@R4]\] and (2) has lipophilic characteristics, while the most used chemotherapeutic agents, e.g., doxorubicin, are hydrophilic. The embolic agent DEB shows a well-calculable binding and release of chemotherapeutics, but causes a permanent vascular occlusion \[[@R7]\]. The duration of the occlusion is of importance since the dependent release of vascular endothelial growth factor (VEGF) can promote metastatic seeding. Degradable starch microspheres (DSM), such as EmboCept (PharmaCept GmbH, Berlin, Germany), combine a well-defined transient vascular occlusion and optimized binding capacities for chemotherapeutic agents \[[@R8], [@R9]\]. This study presents results on the clinical efficacy, toxicity, and safety of DSM-TACE using EmboCept microspheres for the treatment of intermediate stage HCC.

RESULTS {#s2}
=======

Fifty patients were included between January 2010 and March 2015. They received a total of 179 DSM-TACE procedures. The youngest patient was 44 years old upon inclusion in the study, and the oldest patient was 83 years old (mean ± SD = 67.7 ± 10 years; Table [1](#T1){ref-type="table"}). HCC was surgically pre-treated in 4 patients (8.0 %) before chemoembolization, and one patient (2.0 %) underwent radiofrequency-ablation (RFA). HCC metastases were not surgically pre-treated in any patients. Systemic chemotherapy preceded DSM-TACE in 2 patients (4.0 %).

###### Baseline characteristics of patients, pre-treatment, and disease extent

  ---------------------------- -------------------------------
  Age (mean ± SD; min; max)    67.7 ± 10; 44; 83 years
  Pre-treatment                
   Surgery                     4/50 (8.0 %)
   RFA                         1/50 (2.0 %)
   Chemotherapy                2/50 (4.0 %)
  Disease extent               
   \< 4 hepatic metastases     28/50 (56.0 %)
   ≥ 4 hepatic metastases      17/50 (34.0 %)
   no. of metastases unknown   5/50 (10.0 %)
   left lobe                   4/50 (8.0 %)
   right lobe                  20/50 (40.0 %)
   bilobar; no data            17/50 (34.0 %); 9/50 (18.0 %)
   infiltrative growth         11/50 (22.0 %)
   nodular growth              36/50 (72.0 %)
   infiltrative & nodular g.   3/50 (6.0 %)
  ---------------------------- -------------------------------

On inclusion, 28 patients had less than 4 HCC lesions (56.0 %) and 17 patients had 4 or more lesions (34.0 %, no data = 5). These lesions were in the left lobe in 4 patients (8.0 %), in the right lobe in 20 patients (40.0 %), and in both lobes in 17 patients (34.0 %; no data = 9). Infiltrative tumor growth was observed in 11 patients (11.0 %), a nodular growth pattern in 36 patients (72.0 %) and an infiltrative as well as nodular growth pattern in 3 patients (6.0 %).

DSM-TACE {#s2_1}
--------

DSM-TACE was used in a palliative treatment setting in 41 out of 50 cases (82.0 %). In five cases (10.0 %), chemoembolization was initially intended as a curative treatment. In two cases (4.0 %), it was applied before patients were listed for liver transplantation (no data = 1).

Application of DSM-TACE was conducted selectively via A. hepatica propria in 7 procedures (3.9 %), A. hepatica dextra in 48 procedures (26.8 %), both A. hepatica dextra and sinistra in 25 procedures (14.0 %), A. hepatica sinistra in 15 procedures (8.4 %), superselective catheterization in 45 procedures (25.1 %), both superselective catheter placement and selective catheterization of the A. hepatica dextra in 15 procedures (8.4 %) and A. hepatica dextra, A. hepatica sinistra and superselective catheterization in 21 procedures (11.7 %, no data = 3; Table [2](#T2){ref-type="table"}).

###### Details on the TACE procedures

  Catheter position             
  ----------------------------- -------------------------------
   A. hepatica propria (AHP)    7/179 (3.9%)
   A. hepatica dextra (AHD)     48/179 (26.8 %)
   A. hepatica sinistra (AHS)   15/179 (8.4 %)
   AHD + AHS                    25/179 (14.0 %)
   AHD + AHD + superselective   21/179 (11.7 %)
   AHD + superselective         15/179 (8.4 %)
   superselective; no data      45/179 (25.1 %); 3/179 (1.7%)
  DSM dose (mg)                 353.6 ± 140.1
  Contrast agent (ml)           66.1 ± 60.1
  Injection time of CTX (min)   22.9 ± 17.6
  TACE sequence                 
   CTX and DSM combined         172/179 (96.1 %)
   CTX prior to DSM             1/179 (0.6 %)
   DSM prior to CTX; no data    3/179 (1.7 %); 3/179 (1.7 %)

A mean of 353.6 ± 140.1 mg of DSM was used per treatment, and 66.1 ± 60.1 ml of contrast agent was added. Application of chemotherapeutic agents spanned over 22.9 ± 17.6 minutes. DSM was given mixed with chemotherapeutic agents in 172 procedures, following chemotherapeutic agents in 1 case and prior to chemotherapeutic agents in 3 cases (no data = 3).

Doxorubicin, Epirubicin, and Carboplatin were used as the sole chemotherapeutic agent in 174 cases (Table [3](#T3){ref-type="table"}, no data = 5). Doxorubicin was used in 84 cases with dosages from 25 to 50 mg (50 mg n = 70), Epirubicin in 87 cases with dosages from 20 to 100 mg, and Carboplatin in 3 cases with either 300 mg (n = 2) or 450 mg (n = 1).

###### Details on the chemotherapeutic agents used

  Chemotherapeutic agent   Dosage (mg)   n
  ------------------------ ------------- ----
  Doxorubicin              25            10
                           34, 5         1
                           40            3
                           50            70
  Epirubicin               20            1
                           25            1
                           30            4
                           50            52
                           55            5
                           60            21
                           100           2
                           no data       1
  Carboplatin              300           2
                           450           1

Safety {#s2_2}
------

In 2 patients, treatment had to be discontinued because of an allergic reaction to DSM during the first chemoembolization. Within 24 hours of DSM-TACE in 45 treatments (25.2 %), epigastric pain was registered as an immediate AE. Nausea and vomiting occurred after 20 treatments (11.2 %). After 2 treatments (1.1 %), dyspnea occurred, while after 1 treatment (0.6 %), shivering occurred. After 7 treatments (3.9 %), elevated temperature was reported. All adverse events were attributable to 26 of 50 patients. Thus, 24 patients (48.0 %) did not encounter any adverse events, 24 (48.0 %) had minor adverse events (AE), and 2 (4.0 %) had severe adverse events (SAE).

Between DSM-TACE treatments, epigastric pain was registered in 27 cases and nausea and vomiting in 26 cases. After 7 procedures, elevated temperature was reported. In 2 cases, diarrhea occurred. One patient developed a gastric ulcer. Two treatments were followed by transient neutropenia and one by transient thrombopenia. These adverse events were attributable to 26 of 50 patients. In summary, AE occurred in 25 out of 50 patients (50.0 %), and one patient (2.0 %) had a SAE (Figure [1](#F1){ref-type="fig"}).

![Number of patients affected by adverse (AE) and severe adverse events (SAE)\
Immediate events (\< 24 h from DSM-TACE) and delayed events (\> 24 from DSM-TACE).](oncotarget-08-72613-g001){#F1}

Efficacy and tumor response {#s2_3}
---------------------------

Using the mRECIST criteria for the therapeutic efficacy assessment, the results were as follows: CR = 2 % (n=1), PR = 42 % (n=21), SD = 26 % (n=13), and PD = 18 % (n=9); for 12 % of patients (n=6), the follow up data were incomplete (Table [4](#T4){ref-type="table"}). Thus, the objective response (OR) was 44 % (n=22) and disease control (DC) was 70 % (n=35; Figure [2](#F2){ref-type="fig"}).

###### Final tumor response grading using mRECIST

                       mRECIST
  -------------------- -----------
  complete remission   1 (2 %)
  partial remission    21 (42 %)
  stable disease       13 (26 %)
  progress             9 (18 %)
  no data              6 (12 %)
  objective response   22 (44 %)
  disease control      35 (70 %)

![Tumor response of HCC to DSM-TACE\
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease.](oncotarget-08-72613-g002){#F2}

DISCUSSION {#s3}
==========

HCC is the 3^rd^ most common cause of cancer-related death worldwide \[[@R1]\]. Patients and medical professionals often face the challenge of the disease no longer being eligible for curative resection at the time of diagnosis. TACE has proven to be a safe and efficient therapeutic option in treating intermediate stage HCC \[[@R2]\]. It can be both a stand-alone treatment or bridge to other therapies, including resection or transplantation, if sufficient reduction of tumor burden can be realized. TACE comprises a vast field of setups with respect to its two major components: the chemotherapeutic agent and embolic agent. The latter is of major importance for the TACE procedure. The embolic agent delivers the chemotherapeutic agent to the target tissue and causes a vascular occlusion, which is a key component in TACE treatment. First, reduced blood flow extends the exposure time to CTX \[[@R7]\]. Second, the reduced wash out ramps up the locoregional concentration of CTX \[[@R7]\]. Third, ischemia can cause tumor necrosis \[[@R13]\]. Ischemia also causes changes to the cellular signaling pathways, possibly facilitating CTX uptake \[[@R14]\]. Finally, ischemia may facilitate the cytotoxic action of CTX by creating an oxygen-deprived environment that is favorable for free-radical formation \[[@R15]\]. DSM microspheres represent a major class of degradable embolic agents besides conventional Lipiodol and permanent occlusive drug eluting beads. Conventional TACE using Lipiodol has two major disadvantages. First, the lipophilic property reduce its capacity for loading with most chemotherapeutic agents, which are predominantly hydrophilic \[[@R16]\]. Additionally, it has been shown to be associated with a remarkable systemic VEGF (vascular endothelial growth factor) response, which may facilitate tumor growth and metastatic seeding \[[@R17], [@R18]\], which is possibly due to occlusion of the smallest caliber vessels, causing a characteristic ischemia-reperfusion (I/R) timeframe \[[@R14], [@R19]\]. Both DSM and DEB do not elicit this type of dominant VEGF response. Most microspheres and beads are 50 microns or larger, sparing the smallest vessels. With respect to the characterization of I/R, one must consider the unique anatomic properties of the liver with the dual blood supply, which is dominated by the portal vein (approx. 80%) and complemented by the hepatic artery (approx. 20%). Furthermore, this demands a clear and strict separation from the observation and evaluation of primary liver cancers, such as HCC with a hypervascular architecture, and secondary liver malignancies, such as colorectal metastasis. With respect to the combined results (metastases and HCC) published by Sun et al. for HepaSphere microspheres (Merit Medical Systems Inc., South Jordan, UT, USA) \[[@R20]\], our results showed a promising objective response rate of 44 %, and disease control rate of 70 %, which is worthy of further evaluation in randomized clinical trials. The safety and toxicity profile of Embocept DSM-TACE was very favorable in our cohort, which was composed of 179 DSM-TACE procedures in 50 patients with intermediate stage, non-resectable HCC. Kirchhoff et al. reported partial remission in 36 % of patients and no complete remission using degradable starch microspheres and Lipiodol \[[@R21]\]. In 2014, Malagari et al. reported an objective response rate of 68.9 % using DSM-TACE \[[@R16]\]. Largely, the results of TACE-treatment in liver malignancies vary widely. This is due, but not limited, to non-standardized TACE procedures and applications, different embolic agents, different chemotherapeutic agents, different pre-treatments, varying treatment concepts (stand-alone TACE vs. bridging), small cohort sizes, predominant single-center studies, different tumor entities and tumor burden. Further, multi-center randomized clinical trials must be performed to compare strict, standardized TACE-procedures to gain further insight into which embolic/chemotherapeutic agent combination is best for the treatment of HCC.

To specifically gain insights on EmboCept as an embolization agent in DSM-TACE, our study had the following limitations: it was set up as a solely observational study with non-standardized DSM-TACE procedures, including injection and combination of chemotherapeutics, non-strict inclusion and exclusion criteria in a multicenter design, as well as a loose imaging protocol. This study consequently lacked data and dedicated analyses on clinical outcome parameters, such as the local control rate, progression free survival, and overall survival. For a solely observational study, we accepted these limitations in favor of making promising results on the safety and efficacy of DSM-TACE as an available treatment option.

In conclusion, from the data presented here, EmboCept DSM-TACE seems to be a safe treatment option in intermediate stage HCC, and the results regarding its efficacy are promising. Nonetheless, further studies with strict protocols and long-term follow-ups comparing cTACE or DEB-TACE are required.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Patients older than 18 years with confirmed HCC of intermediate stage that was not suitable for resection or any other curative treatment strategy were eligible for inclusion in this study. Both, nodular and infiltrative growth, as well as single-lobar and bilobar disease, were suitable for inclusion. Patients with prior chemoembolization, enrollment in any other clinical trial and/or other contraindications against DSM-TACE, such as lacking safe arterial access to the intrahepatic malignancy, were precluded from participation in the study.

Informed consent and approval by the local ethics committee were waived because the study was solely observational, and the study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guideline on Good Clinical Practice, and national laws and regulations where applicable.

Study design {#s4_2}
------------

This was a national, multi-center observational study on the safety and efficacy of DSM-TACE for the treatment of intermediate HCC. The recruitment period for the study was from January 2010 to June 2014.

### DSM-TACE {#s4_2_1}

EmboCept S DSM 35/50 is a short-term embolizate that is composed of degradable starch microspheres with an average diameter of 50 micrometers. The microspheres are enzymatically degraded by serum alpha-amylases in the blood, yielding a half-life of approximately 35-50 minutes, both *in vivo* and *in vitro*. The resulting glucose fragments are further degraded by the reticulocyte system. A specific side-effect of the transient vascular occlusion strategies, such as in TACE, is the back-flow of the embolizate to non-target regions, causing ischemia and severe pain. DSM ameliorates the risk of profound organ damages due to its self-limiting degradation. With degradable starch microspheres, partial resumption of blood flow is observed after approximately 10 to 15 minutes \[[@R10]\].

After inclusion and imaging (MRI and/or CT), patients received DSM-TACE. Six weeks later, patients were restaged and received another cycle of DSM-TACE when suitable.

A catheter for DSM-TACE was placed via the femoral artery in all patients. Selective (A. hepatica propria, A. hepatica sinistra, A. hepatica dextra) or super-selective catheterization was subject to discretion by the interventionalist in charge depending on the tumor burden, vascular status, and individual patient and case characteristics.

The preparation and dosage of DSM was in line with the manufacturer\'s instructions. The choice of chemotherapeutic agent or a combination of up to three drugs was used depending on the individual patient and case characteristics. DSM allows for the use of different types of co-administered contrast agents. As in all TACE procedures, the order of application of the embolizate and chemotherapeutic agent was as follows: the embolizate was applied first, followed by the chemotherapeutic(s) or both in parallel.

### Imaging {#s4_2_2}

Within this observational study, the imaging modality for the staging of the intrahepatic lesions was chosen according to institution and/or interventionalist preference. Before and after DSM-TACE, all patients underwent CT or MR imaging using a multiphase liver imaging protocol. All patients underwent the same imaging modalities throughout their participation in the study to enable a reliable rating according to mRECIST.

### Safety {#s4_2_3}

A key point of the observational study reported here was to evaluate the DSM-TACE treatment-emergent side effects. The side effects were separately registered within 24 hours of the TACE-procedure (immediate). The side effects between single treatment sessions (delayed) were based on the CTCAE (Common Terminology Criteria for Adverse Events) V4.0 classification of acute and subacute toxic side effects, covering both serious adverse events (SAE) and adverse events (AE).

### Efficacy {#s4_2_4}

The efficacy of DSM-TACE in HCC treatment was rated according to mRECIST for the assessment of tumor necrosis in locoregional therapies \[[@R11], [@R12]\]. Complete response (CR) was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameters of viable (contrast enhancing) target lesions. Progressive disease (PD) was defined as an increase of at least 20% in the sum of the diameters of the viable (enhancing) target lesions, and stable disease included all cases that did not qualify as a either partial response or progressive disease. As previously reported \[[@R5]\], disease control (DC) was defined and calculated as CR + PR + SD. Objective response (OR) was defined and calculated as CR + PR.

Statistical analysis {#s4_3}
--------------------

For statistical calculations, analysis, and plotting, we used GraphPad Prism version 5.00a for Mac (GraphPad Software, San Diego California, U.S.A.). Statistically significant differences were assumed at p \<0.05.
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